Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 1 country.
Luiza Tamie Hirata DiethelmLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Departamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Jundiaí 13202-550, Brazil.
Amanda Bruno da Silva Bellini RamosDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas 37130-001, Brazil.
Giovanna Braga de LorenaLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Departamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Jundiaí 13202-550, Brazil.
Bruna Inácio TrajanoInstitute of Chemistry, State University of Campinas, Campinas 13083-970, Brazil.
Rafael Dias do Espírito SantoInstitute of Chemistry, State University of Campinas, Campinas 13083-970, Brazil.ORCID 0000-0002-3566-1832
Renata Priscila Barros de MenezesPrograma de Pós-Graduacão em Produtos Naturais e Sintéticos Bioativos (PgPNSB), Instituto de Pesquisa em Fármacos e Medicamentos (IPeFarM), Universidade Federal da Paraíba, João Pessoa 58051-900, Brazil.ORCID 0000-0003-2718-4914
Marcus Tullius ScottiPrograma de Pós-Graduacão em Produtos Naturais e Sintéticos Bioativos (PgPNSB), Instituto de Pesquisa em Fármacos e Medicamentos (IPeFarM), Universidade Federal da Paraíba, João Pessoa 58051-900, Brazil.ORCID 0000-0003-4863-8057
Fabio Antonio ColomboDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas 37130-001, Brazil.ORCID 0000-0002-1596-9709
Marcos José MarquesDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Alfenas 37130-001, Brazil.
Carlos Roque Duarte CorreiaInstitute of Chemistry, State University of Campinas, Campinas 13083-970, Brazil.ORCID 0000-0001-5564-6675
Juliana Quero ReimãoLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Departamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Jundiaí 13202-550, Brazil.ORCID 0000-0002-4418-0838
Faculdade de Medicina de Jundiaí · BRUniversidade Estadual de Campinas (UNICAMP) · BRUniversidade Federal de Alfenas · BRUniversidade Federal da Paraíba · BR
Funding
National Council for Scientific and Technological Development 406643/2018-0 and 306773/2018-0São Paulo Research Foundation 2014/07600-3, 2018/18954-4, 2020/03399-5 and 2023/00383-9
6 · The paper itself
Abstract
Toxoplasmosis is a globally prevalent zoonotic disease with significant clinical implications, including neurotoxoplasmosis, a leading cause of cerebral lesions in AIDS patients. The current pharmacological treatments for toxoplasmosis face clinical limitations, necessitating the urgent development of new therapeutics. Natural sources have yielded diverse bioactive compounds, serving as the foundation for clinically used derivatives. The exploration of marine bacteria-derived natural products has led to marinoquinolines, which feature a pyrroloquinoline core and demonstrate in vitro and in vivo anti-
Indexed as
anti-T. gondii activityin vitro evaluationin vivo efficacymarinoquinolinesneurotoxoplasmosistherapeuticstoxoplasmosis
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
First Description of Marinoquinoline Derivatives' Activity against · full record | OpenQuestion